METHODS	Subjects aged 3-8 years ( n = 194 ) and 9-17 years ( n = 160 ) were randomized to receive two primary doses of A/H1N1 vaccine containing either 3.75 g antigen with half a standard dose of MF59 adjuvant , 7.5 g antigen with a full dose of MF59 , or ( children 3-8 years only ) , a non-adjuvanted 15 g formulation .\